Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
NCT03382574 · National Cancer Institute (NCI) · EARLY_PHASE1 · terminated · last registry update 2022-06-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-10Phase 3 first posted: Luye Pharma Group Ltd., Denosumab (NCT05853354)
- 2023-04-14Phase 3 first posted: Shanghai JMT-Bio Inc., Narlumosbart + Denosumab (NCT05813665)
- 2023-03-14Also stopped (withdrawn): Shenzhen People's Hospital, Denosumab Only Product (NCT05065164)
- 2023-03-08Results posted on the registry: Sandoz, GP2411 + EU-Prolia (EU-authorized Prolia®) (NCT03974100)
- 2023-02-15Results posted on the registry: University of Rochester, Denosumab (NCT03839459)
- 2022-12-28Results posted on the registry: Amgen, Denosumab (NCT02352753)
- 2022-12-28Also stopped (terminated): Amgen, Denosumab (NCT02352753)
- 2022-12-20Results posted on the registry: Amgen, Denosumab + Alternative osteoporosis medications (NCT03638128)
- 2022-12-20Also stopped (terminated): Amgen, Denosumab + Alternative osteoporosis medications (NCT03638128)
- 2022-12-06Phase 3 first posted: Shenzhen People's Hospital, Denosumab 60 mg/ml [Prolia] + Zoledronate (NCT05638399)
- 2022-11-02Results posted on the registry: Columbia University, Denosumab (NCT01558115)
- 2022-11-02Also stopped (terminated): Columbia University, Denosumab (NCT01558115)
- 2022-10-12Results posted on the registry: Massachusetts General Hospital, Denosumab 60 MG [Prolia] + Placebo Injection (NCT03292146)
- 2022-06-15Phase 3 first posted: Lambda Therapeutic Research Ltd., Denosumab + Denosumab-Ref (NCT05419427)
- 2022-06-06Phase 3 first posted: Enzene Biosciences Ltd., ENZ215 + Prolia (NCT05405725)
- 2022-05-27Phase 3 first posted: Alvotech Swiss AG, AVT03 + Denosumab (NCT05395091)
- 2022-04-28Phase 3 first posted: Shanghai Henlius Biotech, HLX14 + Prolia® (NCT05352516)
- 2022-04-26Phase 3 first posted: Biocon Biologics UK Ltd, Bmab 1000 + Prolia® (NCT05345691)
- 2022-04-20Phase 3 first posted: mAbxience Research S.L., MB09 (denosumab biosimilar) + EU-Prolia (NCT05338086)
- 2021-11-03Phase 3 first posted: Shenzhen People's Hospital, Denosumab + Zoledronic acid (NCT05106517)
- 2021-10-22Also stopped (terminated): Centre Leon Berard, denosumab (NCT03408652)
- 2021-10-21Phase 3 first posted: Gedeon Richter Plc., RGB-14-P + Prolia® (NCT05087030)
- 2021-10-07Results posted on the registry: M.D. Anderson Cancer Center, Ra-223 dichloride + Denosumab (NCT02366130)
- 2021-10-01Phase 3 first posted: Shenzhen People's Hospital, Denosumab Only Product (NCT05065164)
- 2021-09-28Also stopped (terminated): Amgen, Placebo + Denosumab (NCT01077154)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision